Adolescent cannabis use is associated with an increased risk for new psychiatric disorders during key developmental stages.

FDA expands Juxtapid approval for pediatric patients aged 2 years and older with homozygous familial hypercholesterolemia to reduce plasma LDL-C levels.

Treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity are under review.

Telemedicine for certain conditions may be cheaper and lead to fewer short-term follow-up visits, reducing the overall cost of care burden.

The HHS pushes for additional nutrition training in medical schools, some experts agree but approach the implementation with skepticism.